• New Immunotherapy Approach Hits the Sweet Spot with Solid Tumors

    Bio-IT World | Glycans, the complex sugar chains found at abnormally high levels on the surface of cancer cells, have historically been difficult to target effectively with traditional antibody therapies. One of the biggest reasons is that T cells can’t present glycans to B cells so they can make antibodies that bind strongly and stably to the target antigen.

    Oct 15, 2025

  • TOR Inhibitors Could One Day Be Multi-Purpose Healthspan Drugs

    Bio-IT World | The Target of Rapamycin (TOR) signaling pathway is a prime target for therapeutic development, since its dysregulation is implicated in promoting aging and a range of age-related diseases. By inhibiting TOR, the prescription medication rapamycin has been successfully used to prevent organ transplant rejection and treat certain cancers, but its use for anti-aging purposes in healthy individuals has yet to be approved by the Food and Drug Administration (FDA).

    Oct 14, 2025

  • Boltz Upgrade: Recursion Researchers Release Pipeline Combining AI Binding Model with Absolute Binding Free Energies

    Bio-IT World | Researchers from Recursion are further developing their work on protein-ligand docking with a new digital tool: the Boltz-ABFE pipeline. This summer, with researchers from MIT, Recursion researchers released Boltz-2, an updated artificial intelligence model that can predict protein structure and binding affinity.

    Oct 10, 2025

  • Former Musician Casey McPherson Tackles Rare Disease Cures Through Biotech

    Bio-IT World | Over 10,000 rare diseases affect millions worldwide, yet fewer than 5% have treatments. Musician-turned-biotech founder Casey McPherson is rewriting the playbook for rare disease research and drug development, which he discusses in the latest episode of Trends from the Trenches.

    Oct 10, 2025